FENC Q1 2025 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

FENCFennec Pharmaceuticals Inc.

$220M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-65.5% YoY

Gross Profit

$8M95.7% margin

Operating Income

-$808,000-9.2% margin

Net Income

-$1M-13.3% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

+10.4%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$798,000

Balance Sheet

Total Assets

$46M

Total Liabilities

$52M

Stockholders' Equity

-$6M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$25M	-65.5%
Gross Profit	$8M	$25M	-66.3%
Operating Income	-$808,000	$14M	-105.9%
Net Income	-$1M	$13M	-109.1%